Scarica l'app Stockscreener
0.6223
1.34%
0.0082
Pre-mercato:
.62
-0.0023
-0.37%
Context Therapeutics Inc Borsa (CNTX) Ultime notizie
Context Therapeutics Inc (CNTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CNTX|Context Therapeutics Inc|Price:0.620|Chg%:+0.006 - TradingKey
BlackRock (NYSE: BLK) discloses 6.7% ownership of Context Therapeutics (CNTX) - Stock Titan
Context Therapeutics Inc (CNTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Context Therapeutics Inc (CNTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Context Therapeutics Inc (CNTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Context Therapeutics, Inc. Revenue Breakdown – DUS:6K9 - TradingView
Context Therapeutics Inc (CNTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Context Therapeutics Inc (CNTX) Institutional Confidence - TradingKey
Context Therapeutics, Inc. Revenue Breakdown – SWB:6K9 - TradingView
Context Therapeutics Inc. Revenue Breakdown – BOATS:CNTX - TradingView
SRNE stock holds on Sorrento Therapeutics identity and filing context - ad-hoc-news.de
Enterprise value to revenue forward of Context Therapeutics, Inc. – DUS:6K9 - TradingView
Enterprise value to EBITDA forward of Context Therapeutics, Inc. – DUS:6K9 - TradingView
Context Grants 146,000-Share Option to New Employee - MyChesCo
Context Therapeutics Q1 2026 Earnings: EPS Beat by 24.81% Offset by Stock Decline Amid Pre-Revenue Stage - dars.gov.et
Context Therapeutics (CNTX) Proxy filing Summary - Quartr
Context Therapeutics (CNTX) Leerink Global Healthcare Conference 2026 Summary - Quartr
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Context Therapeutics hire receives 146,000-share stock option at $0.70 - Stock Titan
Context Therapeutics Advances First-in-Human CT-202 Trial, Setting Up a New Nectin-4 Oncology Catalyst - TipRanks
Context Therapeutics Inc (CNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Context Therapeutics Added to Russell 2000 and Russell 3000 Indexes - 富途牛牛
Context Therapeutics (CNTX) Surges Nearly 10% as Momentum BuildsSafe Entry Stocks - dars.gov.et
Context Therapeutics Joins Russell 2000, Russell 3000 Indexes - Moomoo
Context Therapeutics stock rises on Russell index inclusion By Investing.com - Investing.com Nigeria
Context Therapeutics stock rises on Russell index inclusion - Investing.com
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes - GlobeNewswire
Diluted net income available to common stockholders of Context Therapeutics, Inc. – DUS:6K9 - TradingView
Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish - Yahoo Finance
Context Therapeutics (CNTX) Gains 7.46% as Stock Tests Key Resistance at $0.68Social Sentiment - dars.gov.et
Context Therapeutics Inc. (CNTX) Rallies Over 7% on Elevated Volume, Approaching Key ResistanceBPI Bull Correction - dars.gov.et
Context Therapeutics Inc.(NasdaqCM:CNTX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 2500 Growth Benchmark - marketscreener.com
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 2000 Index - marketscreener.com
Context Therapeutics Inc.(NasdaqCM:CNTX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 2000 Growth Benchmark - marketscreener.com
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 3000E Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Context Therapeutics, Inc. – MUN:6K9 - TradingView
Enterprise value to revenue forward of Context Therapeutics, Inc. – MUN:6K9 - TradingView
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 3000E Index - marketscreener.com
Context Therapeutics Shareholders Approve Stock Increase and Directors - The Globe and Mail
Price to book forward of Context Therapeutics Inc. – NASDAQ:CNTX - TradingView
Context Therapeutics (CNTX) director receives grant of 45,000 stock options at $0.576 - Stock Titan
Context Therapeutics (CNTX) director awarded 45,000 stock options at $0.576 - Stock Titan
Context Therapeutics (CNTX) director Linda West awarded 45K stock options - Stock Titan
Director at Context Therapeutics (CNTX) receives 45,000 stock options award - Stock Titan
Director Philip Kantoff receives 45,000 CNTX stock options at $0.576 exercise price - Stock Titan
Context Therapeutics (NASDAQ: CNTX) wins approval to lift share authorization to 300M - Stock Titan
Context Therapeutics, Inc. Actuals & Estimates (NASDAQ:CNTX) - TradingView
Price to sales forward of Context Therapeutics Inc. – NASDAQ:CNTX - TradingView
Price to sales forward of Context Therapeutics, Inc. – GETTEX:6K9 - TradingView
CNTX Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Context Therapeutics, Inc. – GETTEX:6K9 - TradingView
Price to earnings forward of Context Therapeutics Inc. – NASDAQ:CNTX - TradingView
Enterprise value to EBIT forward of Context Therapeutics Inc. – NASDAQ:CNTX - TradingView
CNTX Q1 2026 Earnings: Narrower-than-expected loss drives positive post-market reactionQuarterly Financial Update - dars.gov.et
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):